Drug Profile
RQ 00434739
Alternative Names: CMR-1 anatgonist - RaQualia Pharma; RQ-00434739Latest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator RaQualia Pharma
- Class Analgesics; Anti-inflammatories; Small molecules
- Mechanism of Action TRPM8 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neuropathic pain
- Research Pain
- Discontinued Inflammation
Most Recent Events
- 17 Apr 2024 RaQualia Pharma plans a phase II trial in Pain (RaQualia Pharma pipeline, April 2024)
- 17 Apr 2024 RaQualia Pharma plans a clinical trial for Cancer pain and Neuropathic pain in China and USA (RaQualia Pharma pipeline, April 2024)
- 17 Apr 2024 RaQualia Pharma plans a phase I trial for Pain in Australia (RaQualia Pharma pipeline, April 2024)